ArticleJournal of veterinary internal medicine2021
Continuous rate infusion of midazolam as emergent treatment for seizures in dogs.
Article in Journal of veterinary internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Antiepileptic drug therapy in companion animals: New perspectives on clinical pathology monitoring.Veterinary and animal science · 2026Review
- Single-Dose Pharmacokinetics of Intranasal Levetiracetam in Healthy Dogs.Journal of veterinary pharmacology and therapeutics · 2026Article
- Extended Analysis of Status Epilepticus and Cluster Seizures in Dogs in the Context of Overall Epilepsy Incidence: 254 Cases.Animals : an open access journal from MDPI · 2025Article
- Perspectives on pharmacologic strategies in the management of meningoencephalomyelitis of unknown origin in dogs.Frontiers in veterinary science · 2023Review
- Duration of constant rate infusion with diazepam or propofol for canine cluster seizures and status epilepticus.Frontiers in veterinary science · 2023Article
- Constant rate infusion of diazepam or propofol for the management of canine cluster seizures or status epilepticus.Frontiers in veterinary science · 2022Article
- Continuous rate infusion of midazolam as emergent treatment for seizures in dogs.Journal of veterinary internal medicine · 2021Article
- ACVIM Consensus Statement on the management of status epilepticus and cluster seizures in dogs and cats.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundMidazolam delivered by continuous rate infusion (CRI) might be effective in dogs with cluster seizures (CS) or status epilepticus (SE).
objectiveTo describe the use and safety of midazolam CRI in dogs with CS or SE. ANIMALS: One-hundred six client-owned dogs presenting to a veterinary teaching hospital with CS or SE.
methodsRetrospective review of medical records for dogs with CS or SE treated with a midazolam CRI.
resultsSeventy-nine dogs presented with CS and 27 dogs had SE. Seizure control was achieved in 82/106 dogs (77.4%) receiving a midazolam CRI. The median dose associated with seizure control was 0.3 mg/kg/h (range, 0.1-2.5 mg/kg/h). The median duration of CRI was 25 hours (range, 2-96 hours). Seizures were controlled in 34/40 dogs (85%) with idiopathic epilepsy, 32/43 dogs (74%) with structural epilepsy, 12/16 dogs (75%) with unknown epilepsy, and 4/7 dogs (57%) with reactive seizures (P = .20). Seizure control was achieved in 81% of dogs with CS and 67% in dogs with SE (P = .18). Dogs with idiopathic/unknown epilepsy were more likely to survive than those with structural epilepsy (87% vs 63%, P = .009). Adverse effects were reported in 24 dogs (22.6%) and were mild in all cases. CONCLUSIONS AND CLINICAL IMPORTANCE: Midazolam CRI is apparently safe and might be an effective treatment in dogs with CS or SE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.